In a multicenter, randomized, double-blind, placebo-controlled, noninferiority trial, we enrolled 5246 men 45 to 80 years of age who had preexisting or a high risk of cardiovascular disease and who ...
The cardiovascular polypill, developed by the Spanish National Centre for Cardiovascular Research (CNIC) and the pharmaceutical company Ferrer, has been included by the World Health Organization (WHO) ...
Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular ...
The American College of Cardiology’s (ACC’s) five-year Strategic Plan includes a major initiative focused on transforming care delivery in new areas and recognizing the importance of delivering care ...
Mehran begins a one-year term leading premiere global cardiovascular WASHINGTON, March 30, 2026 /PRNewswire/ -- Roxana Mehran, MD, FACC, today assumed the role of president of the American College of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results